Table 2.
Mean change from baseline in circulating vitamin D metabolites, plasma PO4, and FGF-23 by study group.
| Characteristics | Vitamin D group | Placebo group | Treatment effect | P value3 | ||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Follow-up (36 months) | Mean change from baseline1 | Baseline | Follow-up (36 months) | Mean change from baseline1 | Adjusted between-group differences2 | ||
| 25OHD (nmol/L) | 36.9 (32.8–40.9) | 100.3 (87.6–112.9) | 65.8 (54.5 to 77.1)∗∗∗ | 36.7 (32.8–40.6) | 46.9 (41.4–45.3) | 9.6 (3.8 to 15.4)∗∗∗ | 50.5 (37.9 to 63.2) | <0.001 |
| 1,25(OH)2D pmol/L) | 82.0 (75.1–88.8) | 96.5 (85.8–105.2) | 12.2 (3.2 to 21.3)∗∗ | 90.4 (82.3–98.5) | 82.7 (74.7–90.9) | −8.1 (−15.8 to −0.6)∗ | 18.3 (7.3 to 29.3) | <0.001 |
| Phosphate (mmol/L) | 0.88 (0.84–0.93) | 1.09 (0.92–1.27) | 0.21 (0.05 to 0.37)∗∗ | 0.98 (0.93–1.03) | 0.96 (0.91–1.01) | 0.00 (−0.07 to 0.06) | 0.18 (−0.00 to 0.35) | 0.051 |
| FGF-23 (RU/mL) | 146 (106–187) | 977 (135–1819) | 811 (−2 to 1623) | 179 (88–268) | 304 (154–454) | 132 (14 to 250)∗ | 685 (−213 to 15,850) | 0.134 |
1Change from baseline data is shown as mean and 95% confidence interval of the mean; 2between group differences at study termination, with adjustments for baseline values, and initial age and phosphate level; 3probability of between group differences at study termination, with adjustments for baseline values and initial age, phosphate, and aldosterone levels (ANCOVA). ∗ P < 0.05 versus baseline; ∗∗ P < 0.01 versus baseline; ∗∗∗ P < 0.001 versus baseline (Wilcoxon test). 1,25(OH)2D: 1,25-dihydroxyvitamin D; 25OHD: 25-hydroxyvitamin D; FGF: fibroblast growth factor.